Vol 12, Supp. D (2021)
Case report
Published online: 2022-11-07

open access

Page views 122
Article views/downloads 234
Get Citation

Connect on Social Media

Connect on Social Media

Midostaurin added to standard therapy in FLT3-positive acute myeloid leukemia treatment

Andrzej Szczepaniak1, Zuzanna Rzetelska1

Abstract

Acute myeloid leukemia (AML) is a complex disease with a dynamic course associated with a series of acquired and cumulative genetic changes. In recent years, significant advances have been made in understanding of its pathogenesis. Moreover, diagnostic and therapeutic options have expanded. The current classifications take into account cytogenetic and molecular disorders, including the presence of, among others, mutations within FLT3 transmembrane tyrosine kinase, regulating the proliferation and differentiation of hematopoietic cells at an early development stage. FLT3 mutation is detected in approximately 30% of newly diagnosed AML cases and concerns mutations: ITD (internal tandem duplication) or TKD (tyrosine kinase domain) gene. The high ratio of FLT3-ITD. mutation is associated with an unfavorable prognosis. The patients should be included into clinical trials due to insufficient standard therapy effects. The new AML treatment strategies include tyrosine kinase inhibitors, 1st and 2nd generation. Midostaurin is a non-specific kinase inhibitor registered for the treatment of newly diagnosed AML patients in 2017. The paper presents the experience of the Department of Hematology and Bone Marrow Transplantation in Poznan in the use of FLT3 tyrosine kinase inhibitors based on a case report of two patients with newly diagnosed AML.

Article available in PDF format

View PDF Download PDF file



Hematology in Clinical Practice